CJC-1295 / Ipamorelin (NO DAC)
CJC-1295 NO DAC 5 mg + Ipamorelin 5 mg
Research on short-acting growth hormone pathways involved in tissue repair, metabolism, and recovery.
CJC-1295 (no DAC) / Ipamorelin Blend
The CJC-1295 (no DAC) / Ipamorelin blend combines two peptides that stimulate endogenous growth hormone (GH) release through distinct but complementary mechanisms. CJC-1295 (no DAC) is a short-acting analog of Growth Hormone Releasing Hormone (GHRH 1-29) that binds to pituitary GHRH receptors to trigger GH secretion in a pulse-like pattern similar to natural physiology. Ipamorelin is a selective Growth Hormone Secretagogue Receptor (GHS-R1a) agonist that mimics ghrelin’s action, further amplifying GH release without significantly increasing cortisol, prolactin, or appetite.
“No DAC” means the peptide does not include DAC (Drug Affinity Complex). Without DAC, the peptide has a much shorter half-life and is meant for more frequent dosing, typically once or twice a day, so researchers can better control timing and effects.
Research Focus
-
Interaction of GHRH and ghrelin pathways in GH pulse regulation.
-
Study of GH’s role in tissue regeneration and muscle recovery.
-
Effects on lipid metabolism, cellular repair, and energy utilization.
-
Exploration of metabolic adaptation following physical or oxidative stress.
Mechanisms Under Study
-
Synchronized activation of GHRH and GHS-R1a receptors.
-
Pulsatile GH secretion and feedback regulation.
-
Downstream signaling related to regeneration and metabolic balance.
Product Information
-
Supplied as a lyophilized sterile powder.
-
Third-party verified for purity, molecular identity, and composition.
-
For laboratory research use only, not for human or animal use.
